Kevin McNish
`
`From:
`Sent:
`To:
`Cc:
`Subject:
`
`Shishima, Gina <gina.shishima@nortonrosefulbright.com>
`Friday, June 19, 2015 5:30 PM
`Kevin McNish
`Garrett, Mark; Owens, Tom; CeraMedic Service; Andrew Heinz
`RE: IPR2015-01328 Email request for permission from PTAB
`
`Kevin, 
`
`  
`The customers are not RPIs because they did not have knowledge of or participate in the filing of the IPR petition.    
`
`  
`The grant of CeramTec’s request will not prevent CeraMedic from challenging CeramTec’s RPI designation.  Moreover, 
`by CeraMedic’s logic, it would render this IPR petition fatally defective.  Therefore, please explain CeraMedic’s 
`opposition to the request. 
` 
`CeramTec does not intend to withdraw the IPR petition (IPR2015‐01328). 
`
` I
`
` will send the request to the PTAB later today and note your opposition.   
`
` 
`Regards, 
`Gina 
`
`  
`
`From: Kevin McNish [mailto:KMcNish@desmaraisllp.com]
`Sent: Thursday, June 18, 2015 11:16 PM
`To: Shishima, Gina
`Cc: Garrett, Mark; Owens, Tom; CeraMedic Service; Andrew Heinz
`Subject: RE: IPR2015-01328 Email request for permission from PTAB
` 
`Gina, 
` 
`CeraMedic opposes CeramTec’s request.  Please explain CeramTec’s basis for seeking to remove its customers as RPIs in 
`Case IPR2015‐01328.  Please also explain why CeramTec, if it removes its customers as RPIs in Case IPR2015‐01328, 
`should be allowed to proceed on a petition that CeramTec knows does not name all RPIs. 
`
` I
`
` will follow up with my availability for a conference call with the Board next week in a subsequent email.  And further to 
`my letter of June 10, 2015, please advise tomorrow, June 19, whether CeramTec will be withdrawing the Petition in Case 
`IPR2015‐01328. 
` 
`Regards, 
`Kevin 
` 
`Kevin K. McNish | Associate 
` 
`DESMARAIS LLP 
`230 Park Avenue 
`New York, NY  10169 
`T: (212) 351‐3400 | F: (212) 351‐3401 
`D: (212) 808‐2954 | E: kmcnish@desmaraisllp.com 
`
`1
`
`Exhibit 2314 Page 001
`
`CeraMedic Ex. 2314
`CeramTec GmbH v. CeraMedic LLC
`Case IPR2015-01328
`
`

`
`   
`
`From: Shishima, Gina [mailto:gina.shishima@nortonrosefulbright.com]
`Sent: Thursday, June 18, 2015 7:22 PM
`To: Kevin McNish; CeraMedic Service
`Cc: Garrett, Mark; Owens, Tom; Andrew Heinz
`Subject: IPR2015-01328 Email request for permission from PTAB
` 
`Kevin, 
` 
`Tomorrow we are going to ask permission from the PTAB to file by no later than June 30 an amended Mandatory Notice 
`to remove the Real Parties in Interest (RPIs) that were identified in the IPR petition filed on June 8, 2015.  
` 
`Please indicate whether you will oppose this request.  Should the PTAB ask for a telephone conference with the parties 
`to discuss this request, please provide dates/times for a conference call with the PTAB next week.  
` 
`Thank you, 
` 
`Gina Shishima, Ph.D. | Head of IP Transactions and Patent Prosecution, United States 
`Norton Rose Fulbright US LLP
`98 San Jacinto Boulevard, Suite 1100, Austin, Texas 78701-4255, United States
`Tel +1 512 536 3081 | Fax +1 512 536 4598
`gina.shishima@nortonrosefulbright.com
`
`NORTON ROSE FULBRIGHT
`
`Law around the world
`nortonrosefulbright.com
`
`Norton Rose Fulbright – top 3 global legal brand: Acritas’ Sharplegal 2014 Global Elite Brand Index
`
` 
`
`CONFIDENTIALITY NOTICE: This email, including any attachments, is confidential and may be privileged. If you are not
`the intended recipient please notify the sender immediately, and please delete it; you should not copy it or use it for any
`purpose or disclose its contents to any other person. Norton Rose Fulbright entities reserve the right to monitor all email
`communications through their networks.
`
`Norton Rose Fulbright Australia, Norton Rose Fulbright LLP, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright
`South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton
`Rose Fulbright Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but
`does not itself provide legal services to clients. Details of each entity, with certain regulatory information, are available at
`nortonrosefulbright.com.
`
`
`
`This email may contain confidential and privileged material for the use of the intended recipient. Any review,
`use, or distribution by anyone other than the addressee is strictly prohibited. If you are not the intended
`recipient, please contact the sender by reply email and delete all copies of this message.
`
`2
`
`Exhibit 2314 Page 002
`
`CeraMedic Ex. 2314
`CeramTec GmbH v. CeraMedic LLC
`Case IPR2015-01328